Worth reading
44Recurring
Scored from 4 of 5 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
11638744
Yen (total acquisition price based on the number outstanding as of the current date)Wording
Conditional
How definitive the wording is.Details of issuance or disposal
Acquisition and cancellation of Series 9 and Series 11 stock acquisition rights with exercise price adjustment clauses issued through a third-party allotment (already issued)
Terms of the stock acquisition rights
Exercise price
The share price has remained below the lower exercise price (the specific exercise price and lower limit are Not disclosed)
Number of Stock Acquisition Rights
Total issued: 5,000 Series 9 rights and 30,000 Series 11 rights. Unexercised as of 22 July 2026: 5,000 Series 9 rights and 8,549 Series 11 rights. All rights remaining as of the acquisition date will be subject to acquisition and cancellation.
Most recent equity financing
7 October 2024: Issuance of Series 9 stock acquisition rights (payment completed), 2 February 2026: Issuance of Series 11 stock acquisition rights (payment completed)
Impact on Business Performance
The acquisition and cancellation of these stock acquisition rights will have a minor impact on results for the fiscal year ending March 2027.
Scheduled acquisition and cancellation date
Acquisition date: 29 July 2026 (scheduled); cancellation date: 31 July 2026 (scheduled)
Acquisition price
Series 9: ¥232 per right; ¥1,160,000 for the amount currently outstanding. Series 11: ¥56 per right; ¥478,744 for the amount currently outstanding. Total: ¥11,638,744 (subject to change depending on exercises through the acquisition date)
| Item | Details |
|---|---|
| Type of issuance or disposal | Acquisition and cancellation of Series 9 and Series 11 stock acquisition rights with exercise price adjustment clauses issued through a third-party allotment (already issued) |
| Exercise price | The share price has remained below the lower exercise price (the specific exercise price and lower limit are Not disclosed) |
| Number of Stock Acquisition Rights | Total issued: 5,000 Series 9 rights and 30,000 Series 11 rights. Unexercised as of 22 July 2026: 5,000 Series 9 rights and 8,549 Series 11 rights. All rights remaining as of the acquisition date will be subject to acquisition and cancellation. |
| Most recent equity financing | 7 October 2024: Issuance of Series 9 stock acquisition rights (payment completed), 2 February 2026: Issuance of Series 11 stock acquisition rights (payment completed) |
| Impact on Business Performance | The acquisition and cancellation of these stock acquisition rights will have a minor impact on results for the fiscal year ending March 2027. |
| Scheduled acquisition and cancellation date | Acquisition date: 29 July 2026 (scheduled); cancellation date: 31 July 2026 (scheduled) |
| Acquisition price | Series 9: ¥232 per right; ¥1,160,000 for the amount currently outstanding. Series 11: ¥56 per right; ¥478,744 for the amount currently outstanding. Total: ¥11,638,744 (subject to change depending on exercises through the acquisition date) |
Items this document does not state (23)
Number of shares to be issued or disposed ofIssue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offering
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The share price has remained below the lower exercise price, preventing the stock acquisition rights from being exercised as planned and meaning that the originally anticipated fundraising has not been achieved. The company will also conduct new fundraising through Series 12 stock acquisition rights and Series 3 unsecured bonds.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.